ARGENX SE-ADR Shares Outstanding 2017-2021 | ARGX

ARGENX SE-ADR shares outstanding history from 2017 to 2021. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
  • ARGENX SE-ADR shares outstanding for the quarter ending June 30, 2021 were M, a NAN% increase year-over-year.
  • ARGENX SE-ADR 2020 shares outstanding were 0.045B, a 17.58% increase from 2019.
  • ARGENX SE-ADR 2019 shares outstanding were 0.039B, a 15.56% increase from 2018.
  • ARGENX SE-ADR 2018 shares outstanding were 0.033B, a 35.79% increase from 2017.
ARGENX SE-ADR Annual Shares Outstanding
(Millions of Shares)
2020 45
2019 39
2018 33
2017 25
2016 19
ARGENX SE-ADR Quarterly Shares Outstanding
(Millions of Shares)
2021-06-30
2021-03-31 50
2020-03-31 43
2019-12-31
2019-06-30
2018-12-31
2018-06-30
2017-12-31
2017-06-30
2016-12-31
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $15.766B $0.042B
argenx SE is a biopharmaceutical company. It focuses on developing antibody-based therapies for the treatment of autoimmune diseases and cancer. The company's product pipeline consists of ARGX-113, ARGX-110 and ARGX-111 which are in clinical trials. argenx SE is based in Breda, the Netherlands.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $132.971B 8.85
Bio-Rad Laboratories (BIO.B) United States $22.624B 48.22
QIAGEN (QGEN) Netherlands $12.001B 20.32
Biohaven Pharmaceutical Holding (BHVN) United States $8.691B 0.00
Emergent Biosolutions (EBS) United States $2.870B 6.92
Arcus Biosciences (RCUS) United States $2.690B 0.00
Myovant Sciences (MYOV) United Kingdom $2.182B 0.00
ADC Therapeutics SA (ADCT) Switzerland $2.045B 0.00
Zymeworks (ZYME) Canada $1.373B 0.00
Ambrx Biopharma (AMAM) United States $0.501B 0.00
SQZ Biotechnologies (SQZ) United States $0.442B 0.00
Enzo Biochem (ENZ) United States $0.174B 51.29